University of Alabama Birmingham
Interplay Between Her2, Parp1, And Nf-Κb In Breast Cancer: Potential Therapeutic Implications
Abstract
dc:description.abstractWe previously reported that HER2+ breast cancers are susceptible to Poly (ADP-Ribose) polymerase inhibitors (PARPi) alone, agents that are efficacious against homologous recombination (HR) deficient tumors. However, this phenomenon was determined to be independent of a HR repair deficiency but rather due to suppression of NF-κB activity and signaling by PARP inhibition. Further, HER2 overexpression itself was necessary and sufficient to confer this susceptibility. Interestingly, PARP1 and phosphorylated RelA/p65 (NF-κB) levels were found to be elevated in human HER2+ breast cancers compared to luminal breast cancers. These data suggest a possible interplay between HER2, PARP1, and NF-κB, and how this interplay influences PARPi sensitivity is the main goal of this dissertation. We hypothesize that the elevated PARP1 protein levels observed in HER2+ breast tumors are regulated at the post-transcriptional level via a microRNA. Due to the fact, that resistance to HER2 agents may activate compensatory mechanisms to maintain downstream signaling we predict HER2+ trastuzumab resistant (TR) breast cancer cells will retain sensitivity to PARPi. Our data indicates that HER2+ breast tumors with high PARP-1 protein levels expressed lower levels of let-7a. We also discovered that PARP1’s was regulated at the post-transcriptional level by the let-7a microRNA in HER2+ breast cancer cells. It was also observed that both pharmacological and genetic inhibition of PARP1 decreased NF-κB activity. Specifically, we observed that suppression of PARP1 levels reduced binding of the p65 transcription factor to the promoter of a NF-κB target gene, interleukin 8 (IL-8). Finally, we detected that HER2+ trastuzumab resistant breast cancer cells remained sensitive to PARPi. In conclusion, our data suggest that an interplay between the HER2, PARP1, and NF-κB signaling pathways exists which may be a determinant behind PARPi susceptibility in HER2+ breast cancer cells. Ultimately, the data from these studies will lead to better understanding of PARP biology and broaden the use of PARPi in the clinic.
Degree
thesis:*- Level thesis:degree_level
- Dissertation
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Wielgos, Monicka Ewa
- Contributors dc:contributor
-
- Eddy S Yang
- Robert Van Waardenburg
- Susan Nozell
- Donald Buchsbaum
- Rajeev Samant
Subjects
dc:subject × 7Identifiers
dc:identifier.*- Repository record dc:identifier
- https://digitalcommons.library.uab.edu/etd-collection/3323